Profits in vaccines
This morning I added Sanofi-Aventis (SNY) to the Barchart Van Meerten New High portfolio They are a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated health care solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of health care products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.
Two of the drugs they produce are two of the most widely marketed drugs on the planet. The A/H1N1 flu vaccine and Plavix. I can't watch an evening of TV without seeing several Plavix commercials. Since I had my flu shot my cravings for corn and mud baths are now under control.
The stock is on a recent climb with 19 new highs in 20 session for a 19.82% price gain last month. Barchart has a 96% buy signal with the stock trading around 33.95 above its 50 day high of 30.27. The stock has a 76.93% 14 day Relative Strength Index and is rising.
General investor sentiment is high with the CAPS members on Motley Fool voting 882 to 41 that the stock will beat the market and the All Stars are in agreement 329 to 11. The Wall Street columnists that Fool follows had 14 positive articles on the stock.
Their major markets of the US and Europe means they are marketing in an area of both public and private health care that can afford their products. With all the recent interest in flu vaccines and diabetes drugs this stock should be a winner.
Jim Van Meerten is an advisor to Marketocracy Capital Management who uses his model portfolios not only to manage their mutual funds but also their clients Separately Managed Accounts. You can read his blogs about those model portfolios and investing here and on Barchart Portfolio Blogs. Please leave a comment below or email mailto:JimVanMeerten@gmail.com
Disclosure: Jim Van Meerten through Marketocracy Capital Management has an interest in the stocks mentioned in this blog.